Given the tumor heterogeneity and diverse clinical manifestations observed in NF1, adopting similar multi-omics approaches could greatly enhance patient stratification, facilitate the discovery of prognostic biomarkers, and improve our understanding of immune evasion mechanisms in NF1-associated tumors. This evidence concerns the gene NF1 and neurofibromatosis type 1.